Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2301 - 2325 of 15217 in total
Synthetic conjugated estrogens A are composed of a blend of the following nine synthetic estrogenic substances: estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β­ dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate, and sodium 17β-estradiol sulfate. This blend of nine estrogen derivatives...
Approved
Matched Description: … dryness, and vulvovaginal atrophy. ... estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control ... after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β­ dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17β-estradiol sulfate, and sodium Δ8,9-dehydroestrone sulfate. This...
Approved
Matched Description: … dryness, and vulvovaginal atrophy. ... estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control ... after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects...
Approved
Matched Iupac: … ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3 …
Matched Description: … Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin …
Matched Categories: … Blood and Blood Forming Organs …
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate...
Approved
Investigational
Matched Iupac: … 5-methyl-1-phenyl-1,2-dihydropyridin-2-one …
Matched Description: … [A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that ... fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells. The latest translates...
Approved
Investigational
Matched Description: … Uriach and Company and even though it is commercialized in different countries it is not approved by ... Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule ... agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and
Matched Categories: … Blood and Blood Forming Organs …
Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.
Approved
Matched Iupac: … 1-[(4-chlorophenyl)(phenyl)methyl]-4-methylpiperazine …
Matched Description: … Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and ... first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals...
Approved
Investigational
Matched Description: … Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible ... VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable …
Matched Categories: … Blood and Blood Forming Organs …
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for...
Approved
Investigational
Matched Iupac: … [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine …
Matched Description: … Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal ... beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and ... G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its...
Approved
Investigational
Withdrawn
Matched Description: … A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. ... (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products …
Matched Categories: … Hormones and Related Agents ... Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Approved
Vet approved
Matched Description: … A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive …
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Approved
Matched Iupac: … (1R)-2-(3-{[(4E)-8-{3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin ... -2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl
Thallous chloride (also known as Thallium(I) chloride) is a colourless solid intermediate in the isolation of thallium from its ores. It is created from the treatment of thallium(I) sulfate with hydrochloric acid. This solid crystallizes in the caesium chloride motif. It is used as a diagnostic radiopharmaceutical. It is used...
Approved
Matched Description: … It is used for diagnosis of heart and parathyroid problems. ... pain or discomfort, chills, confusion, cough, difficulty with breathing, difficulty with swallowing, and
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial...
Approved
Investigational
Matched Iupac: … 5-({5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl}methyl)-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyridin …
Matched Description: … tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. ... Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August ... [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone...
Approved
Investigational
Matched Description: … indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and ... Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved …
Matched Categories: … alpha-Galactosidase, antagonists & inhibitors ... Metabolic Side Effects of Drugs and Substances …
Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium. The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4...
Approved
Matched Description: … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018. ... adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and ... The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April …
An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.
Approved
Investigational
Matched Description: … FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction. The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in...
Approved
Investigational
Matched Description: … results in the destruction of these receptors and a reduction in electrical nerve impulses. ... autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and ... acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission ... currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A histamine H2 agonist used clinically to test gastric secretory function.
Approved
Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M . It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays. Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts...
Approved
Matched Iupac: … benzotriazol-2-yl)-6-{[3-(2H-1,2,3-benzotriazol-2-yl)-2-hydroxy-5-(2,4,4-trimethylpentan-2-yl)phenyl]methyl
Matched Description: … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B ... Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a ... UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of …
Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.
Approved
Investigational
Vet approved
Matched Description: … intramuscular forms, and used to treat a wide variety of infections. ... known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and ... Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is …
Matched Categories: … Alimentary Tract and Metabolism …
Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir[L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.[A235725,A235735] Due to its...
Approved
Investigational
Matched Iupac: … ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy) …
Matched Description: … analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and ... treatment of cytomegalovirus (CMV), BK Virus (BKV), adenoviruses (AdV), and Epstein-Barr virus (EBV) ... against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and
Matched Categories: … Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Approved
Matched Iupac: … benzyl(methyl)(prop-2-yn-1-yl)amine …
Matched Categories: … pargyline and diuretics ... MAO Inhibitors and Diuretics …
Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Approved
Investigational
Matched Iupac: … 3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl …
Matched Description: … It has been approved in South Korea and will be marketed under the brand name Zydena. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer,...
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 2301 - 2325 of 15217 in total